^
Association details:
| Biomarker: | CPS1 overexpression + KRAS mutation + STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | cisplatin (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers
Published date:
03/23/2023
Excerpt:
...we chose a NSCLC PDX adenocarcinoma (LTL-657) from a bank of NSCLC PDXs based on high expression of CPS1 and somatic mutations of KRAS and LKB1...As a single agent, DEX significantly inhibited tumor growth and was nearly as efficacious as cisplatin alone (Figure 4B)….Survival curves also showed that mice treated with DEX alone, CDDP alone or in combination survive significantly longer than untreated mice...
DOI:
10.3389/fonc.2023.1025443
